{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kwon BE"],"funding":["Ministry of Health","National Research Foundation of Korea"],"pagination":["2542"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6830241"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10"],"pubmed_abstract":["Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in <i>Mycobacterium tuberculosis</i> as well as in some non-tuberculous mycobacteria (NTM), such as <i>M. kansasii</i>. <i>M. kansasii</i> is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, which is clinically indistinguishable from tuberculosis. In the current study, we designed a novel cell-based vaccine using B cells that were transduced with vaccinia virus expressing ESAT6 (vacESAT6), and presenting α-galactosylceramide (αGC), a ligand of invariant NKT cells. We found that B cells loaded with αGC had increased levels of CD80 and CD86 after <i>in vitro</i> stimulation with NKT cells. Immunization of mice with B/αGC/vacESAT6 induced CD4<sup>+</sup> T cells produ"],"journal":["Frontiers in immunology"],"pubmed_title":["B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases."],"pmcid":["PMC6830241"],"funding_grant_id":["NRF-2017M3A9C8060390","NRF-2017R1A2B2001963"],"pubmed_authors":["Ahn JH","Jeong H","Kwon BE","Shin SJ","Chang SY","Park EK","Jeong HS","Ko HJ","Yeo SG","Shin E","Lee HJ","Jung YJ","Yoo JS"],"additional_accession":[]},"is_claimable":false,"name":"B Cell-Based Vaccine Transduced With ESAT6-Expressing Vaccinia Virus and Presenting α-Galactosylceramide Is a Novel Vaccine Candidate Against ESAT6-Expressing Mycobacterial Diseases.","description":"Early secretory antigenic target-6 (ESAT6) is a potent immunogenic antigen expressed in <i>Mycobacterium tuberculosis</i> as well as in some non-tuberculous mycobacteria (NTM), such as <i>M. kansasii</i>. <i>M. kansasii</i> is one of the most clinically relevant species of NTM that causes mycobacterial lung disease, which is clinically indistinguishable from tuberculosis. In the current study, we designed a novel cell-based vaccine using B cells that were transduced with vaccinia virus expressing ESAT6 (vacESAT6), and presenting α-galactosylceramide (αGC), a ligand of invariant NKT cells. We found that B cells loaded with αGC had increased levels of CD80 and CD86 after <i>in vitro</i> stimulation with NKT cells. Immunization of mice with B/αGC/vacESAT6 induced CD4<sup>+</sup> T cells produ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019","modification":"2025-06-01T12:39:17.896Z","creation":"2025-06-01T12:39:17.896Z"},"accession":"S-EPMC6830241","cross_references":{"pubmed":["31736965"],"doi":["10.3389/fimmu.2019.02542"]}}